medigraphic.com
ISSN 1029-3043 (Electronic)

2020, Number 3

<< Back Next >>

Medicentro 2020; 24 (3)

Understanding the COVID 19

Bonilla SOA

Language: Spanish
References: 118
Page: 595-629
PDF size: 683.86 Kb.


ABSTRACT

Introduction: SARS CoV 2 was recently isolated from human airway epithe lial cells in January 2020 . This virus has caused a pandemic that challenges the global public health infrastructure.
Objective: to review the available bibliography on COVID 19.
Methods: a systematic review of publications in Medline and P ubMed databases was performed using the following key words : COVID 19, COVID 2019, severe acute respirat ory syndrom e coronavirus 2 , 2019 nCoV, SARS CoV 2, 2019 nCoV, Wuhan, and coronavirus.
Conclusions: there were selected forty two publications which were important to understand the pathogenic characteristics of COVID 19 in the context of the pandemic dec lared by the World Health Organization.


REFERENCES

  1. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17:181 92.

  2. Lu H, Stratton CW, Tang YW. Outbreak of pn eumonia of unknown etiology in W uhan China: the mystery and the miracle. J Med Virol. 2020;92(4):401 2.

  3. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497 506.

  4. World Health Organization. Novel Coronavirus China [internet]. Geneva: WHO; 2020 [citado 1 feb. 2020]. Disponible en: https://www. who. int/csr/don/12 january 2020 novel coronavirus china/en/

  5. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS CoV 2) and corona virus disease 201 9 (COVID 19): the epidemic and the challenges. Int J Antimicrob Agents. 2020;55(33):105924.

  6. Weiss SR, Leibowitz JL. Coronavirus pathogenesis. Adv Virus Res. 2011;81:85 164.

  7. Su S, Wong G, Shi W, Liu J, Lai A, Zhou J, et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 2016;24(6):490 502.

  8. Isaacs D , Flowers, Clarke JR, Valman HB, MacNaughton MRl. Epidemiology of coronavirus respiratory infections. Arch Dis Child. 1983;58(7):500 03.

  9. Greenberg SB. Up date on human rhinovirus and coronavirus infections. Semin Respir Crit Care Med. 2016;37(4):555 71.

  10. World Health Organization. Novel coronavirus (2019 nCoV) situation Report 7 [internet]. Geneva: WHO; 2020 [citado 27 ene. 2020]. Disponible en: https://apps. who. int/iris/handle/10665/330771

  11. Zaki AM, Van Boheemen S, Bestebroer TM, Osterhaus A, Fouchier R. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Me d. 2012;367:1814 20.

  12. Chan Yeung M, Xu RH. SARS: epidemiology. Respirology. 2003;8:S9 14.

  13. Panamerican Health Organization/World Health Organization. Middle East Respiratory Syndrome Coronavirus [internet]. Geneva: WHO; 2020 [citado 16 feb. 2020]. Disponible en https://www. paho. org/hq/index. php?option=com_docman&view=list&layou t=table&slug= middle east respiratory syndrome coronavirus mers cov 5384&Itemid=270&lang=en

  14. Zhu N, Zhang DY, Wang WL, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727 33.

  15. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265 9.

  16. Weiss SR, Navas Martin S. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev. 2005;69(4):635 64

  17. Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Nature Public Health Emerg. 2015;1282:1 23.

  18. Zhao L, Jha BK, Wu A, Elliott R, Zeibuhr J, Gorbalenya AE, et al. Antagonism of the interferon induced OAS RNase L pathway by murine coronavirus ns2 protein is required for virus replication and liver pathology. Cell Host Microbe. 2012;11(6):607 16.

  19. Song Z, Xu Y, Bao L, Zang L, Yu P, Qu Y, et al. From SARS to MERS, thrusting coronaviruses into the spotlight. Viruses. 2019;11(1):59.

  20. Zhao Z, Li H, Wu X, Zhong Y, Zhang K, Zhang YP, et al. Moderate mutation rate in the SARS coronavirus genome and its implications. BMC Evol Biol. 2004;4(21).

  21. Woo PC, Lau S, Y ip CC, Huang Y, Tsoi HW, Chan KH, et al. Comparative analysis of 22 coronavirus HKU1 genomes reveals a novel genotype and evidence of natural recombination in coronavirus HKU1. J Virol. 2006 Jul;80(14):7136 45.

  22. Wu D, Zou S, Bai T, Li J, Zhao X, Yang L, et al. Poultry farms as a source of avian influenza a (H7N9) virus reassortment and human infection. Sci Rep. 2015;5:7630.

  23. Tang X, Wu C, Li X, Song Y, Yao X, Wu X, et al. On the origin and continuing evolution of SARS CoV 2. Natl Sci Rev. 2020;nwaa036

  24. Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as causes of pneumonia. Respirology. 2018;23:130 7.

  25. Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol 2020;92(4).

  26. Enjuanes L, Zun iga S, Castano Rodriguez C, Gutierrez Alvarez J, Canton J, Sola I. Molecular basis of coronavirus virulence and vaccine development. Adv Virus Res. 2016;96:245 86.

  27. Ding Y, Wang H, Shen H, Li Z, Geng J, Han H, et al. The clinical pathology of severe acute respiratory syndrome (SARS): a report from China. J Pathol. 2003;200:282 9.

  28. De Wit E, Van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights in to emerging coronaviruses. Nat Rev Microbiol. 2016;14:523 34.

  29. Hui DS, Azhar E. IA, Madani TA, Ntoumi F, Kock R, Dar O, et al. The continuing 2019 nCoV epidemic threat of novel coronaviruses to global health the latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020;91:264 6.

  30. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565 74.

  31. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade long structural studies of SARS. J Virol. 2020;94(7):e00127 20.

  32. Ren LL, Wang YM, Wu ZQ, Xiang ZC, Guo L, Xu T, et al. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chin Med J (Engl). 2020;133(9):1015 24.

  33. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17:181 92.

  34. Paules C I, Marston HD, Fauci AS. Coronavirus infections more than just the common cold. JAMA. 2020;323(8):707 8.

  35. De Wilde AH, Snijder EJ, Kikkert M, Van Hemert MJ. Host factors in coronavirus replication. Curr Top Microbiol Immunol. 2018;419:1 42.

  36. Millet JK, Whittaker GR. Host cell proteases: critical determinants of coronavirus tropism and pathogenesis. Virus Res. 2015;202:120 34.

  37. Simmons G, Gosalia DN, Rennekamp AJ, Reeves JD, Diamond SL, Bates P. Inhibitors of cathepsin L prevent severe acute respi ratory síndrome coronavirus entry. Proc Natl Acad Sci USA. 2005;102(33):11876 81.

  38. Jia HP, Look DC, Shi L, Hickey M, Pewe L, Netland J, et al. ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. J Virol. 2005;79(23):14614 21.

  39. Raj VS, Mou H, Smits SL, Dekkers DK, Muller MA, Dijkman R, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus EMC. Nature. 2013;495:251 4.

  40. Fields BN, Knipe DM, Howley PM, Griffin DE. Fields’ Virology. 5th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2007.

  41. Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak an d modeling of its spike protein for risk of human transmission. Sci Chin Life Sci. 2020;63(3):457 60.

  42. Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS CoV 2 and other lineage B betacoronaviruses. Nat Microbio l. 2020;5:562 9.

  43. Song W, Gui M, Wang X, Xiang Y. Cryo EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2. PLoS Pathog. 2018;14(8):e1007236.

  44. Zhang N, Jiang S, Du L. Current advancements and potential strategies in the development of MERS CoV vaccines. Expert Rev Vaccines. 2014;13(6):761 74.

  45. Yu F, Du L, Ojcius DM, Pan C, Jiang S. Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating i n Wuhan. China. Microbes Infect. 2020;22(2):74 9.

  46. Sawicki SG, Sawicki DL. Coronavirus transcription: a perspective. Curr Top Microbiol Immunol. 2005;287:31 55.

  47. Hussain S, Pan J, Chen Y, Yang Y, Xu J, Peng Y, et al. Identification of novel subgenomic RNAs and noncanonical transcription initiation signals of severe acute respiratory syndrome coronavirus. J Virol. 2005;79(9):5288 95.

  48. Perrier A, Bonnin A, Desmarets L, Danneels A, Goffard A, Rouille Y, et al. The C terminal domain of the MER S coronavirus M protein contains a trans Golgi network localization signal. J Biol Chem. 2019;294(39):14406 21.

  49. World Health Organization. Coronavirus disease 2019 (COVID 19) Situation Report 71 [internet]. Geneva: WHO; 2020 [citado 12 abr. 2020]. Di sponible en: https://www. who. int/docs/default source/coronaviruse/situation reports/20200331 sitrep 71 covid 19. pdf?sfv rsn=4360e92b_8

  50. World Health Organization . Coronavirus disease 2019 (COVID 19) Situation Report 87 [internet]. Geneva: WHO; 2020 [citado 27 mayo 2020]. Disponible en: https://www. who. int/docs/default source/coronaviruse/situation reports/20200416 sitrep 87 covid 19. pdf?sfvrsn=9523115a_2

  51. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus infected pneumonia in Wuhan, China. JAMA. 2020 Mar. 17;323(11):1061 9.

  52. Yang Y, Lu Q, Liu M, Wang Y, Zhang A, Jalali N, et al. Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China. BMJ. (preprints) 2020 [citado 27 mayo 2020]. Disponible en: https://www. medrxiv. org/content/10. 1101/2020. 02. 10. 20021675 v2. article metrics

  53. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus disease (COVID 19) e China. China CDC Weekly. 2020;41(2):145 51.

  54. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507e13.

  55. Guan WJ, Ni ZY, Hu Y, Laing WH, Ou CQ, He JX , et al. Clinical characteristics of 2019 novel coronavirus infection in China. N Engl J Med. 2020;382:1708 20.

  56. Chen H, Guo J, Wang C. Clinical characteristics and intrauterine vertical transmission potential of COVID 19 infection in nine pregnant wome n: a retrospective review of medical records. Lancet. 2020;395(10226):809 15.

  57. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person to person transmission: a s tudy of a family cluster. Lancet. 2020;395:514e23.

  58. Rothe C, Schunk M, Sothmann P. Transmission of 2019 nCoV infection from an asymptomatic contact in Germany. N Engl J Med. 2020;382:970 1.

  59. Kampf G, Todt D, Pfaender S, Steinmann E. Persistence of co ronaviruses on inanimate surfaces and its inactivation with biocidal agents. J Hosp Infect. 2020 Feb. 6; pii: S0195 6701(20)30046 3.

  60. World Health Organization. Situation reports [internet]. Geneva: WHO; 2020 [citado 22 feb. 2020]. Disponible en: https://www. who. int/emergencies/diseases/novel coronavirus 2019/situation reports

  61. Zou L, Ruan F, Huang M. SARS CoV 2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020;382:1177 9.

  62. Liu T, Hu J, Kang M, Lin L, Zhong H, Xiao J, et al. Transmission dynamics of 2019 novel coronavirus (2019 nCoV). Lancet. (preprints) 2020 [citado 6 mayo 2020]. Disponible en: https://www. biorxiv. org/content/10. 1101/2020. 01. 25. 919787v1

  63. Cheng ZJ, Shan J. 2019 novel coronavirus: where we are and what we know. Infection. (preprints) 2020 [citado 6 mayo 20 20]. Disponible en: doi: 10. 20944/preprints202001. 0381. v1

  64. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus infected pneumonia. N Engl J Med. 2020;382:1199 1207.

  65. Bassetti M, Vena A, Roberto Giacobbe D. The Novel Chinese Coronavirus (2019 nCoV) Infections: challenges for fighting the storm. Eur J Clin Invest. 2020;e13209.

  66. National Health Commission of People’s Republic of Ch ina. Pneumonia diagnosis and treatment of 2019 nCoV infection from Chinese NHC and CDC 2020 [internet]. China; 2020 [citado 1 feb. 2020]. Disponible en: http://en. nhc. gov. cn/

  67. National Health Commission of People’s Republic of China. Prevent guideline of 2019 nCoV [internet]. China; 2020 [citado 1 feb. 2020]. Disponible en: http://en. nhc. gov. cn/

  68. Zhang H, Kang Z, Gong H, Xu D, Wang J, Li Z, et al. The digestive system is a potential route of 2019 nCov infection: a bioinformatics analysis based on single cell transcriptomes. bioRxiv. (preprints) 2020 [citado 6 mayo 2020]. Disponible en: https://www. biorxiv. org/content/10. 1101/2020. 01. 30. 927806v1

  69. European Centre for Disease Prevention and Control. Outbreak of acute respiratory syndrome associated with a novel cor onavirus, Wuhan, China; first update [internet]. Europa: E CDC; 2020 [citado 5 feb. 2020]. Disponible en: https:https://www. ecdc. europa. eu/en/publications data/risk assessment outbreak acute respiratory syndrome associated novel coronavirus

  70. American Association of Blood Banks. Update: impact of 2019 novel coronavirus and blood safety [internet]. USA: AABB; 2020 [citado 2 mayo 2020]. Disponible en: http s ://www. aabb. org/advocacy/regulatorygovernment/Documents/ Impact of 2019 Novel Coronavirus on Blood Donation. pdf

  71. Chang Xu H, Rebaza A, Sharma L, Dela Cruz CS. Protecting health care workers from subclinical coronavirus infection. Lancet Respir Med. 2020;8(3):E13.

  72. Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019 nCoV) infected pneumonia (standard version). Mil Med Res. 2020;7(1):4.

  73. Day M. Covid 19: four fifths of cases are asymptomatic, China figures indicate. BMJ. 2020 Apr. 2;369:m1375.

  74. Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt GM, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med. 2003;348(20):1986 94.

  75. Assiri A, Al Tawfiq JA, Al Rabeeah AA. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lan cet Infect Dis. 2013;13:752 61.

  76. Zeng LK, Tao XW, Yuan WH, Wang J, Liu X, Liu ZS. First case of neonate infected with novel coronavirus pneumonia in China. Zhonghua Er Ke Za Zhi. 2020;58:E009.

  77. Wong CK, Lam CW, Wu AK, IP WK, Lee NL, Chan I, et al. Pl asma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2004;136(1):95 103.

  78. Chung M, Bernheim A, Mei X, Zhang N, Huang M, Zeng X, et al. CT imaging features of 2019 novel coronavirus (2019 nCoV). Radiology. 2020;200230.

  79. Lei J, Li J, Li X, Qi X. CT imaging of the 2019 novel coronavirus (2019 nCoV) pneumonia. Radiology. 2020;29 5(1).

  80. Pan Y, Guan H. Imaging changes in patients with 2019 nCov. Eur Radiol. 2020 Feb.

  81. Kanne JP. Chest CT findings in 2019 novel coronavirus (2019 nCoV) infections from Wuhan, China: key points for the radiologist. Radiology. 2020 Feb. 4:200241.

  82. Chan Jasper FW, Yuan SF, Kok KH, Wang KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating personto person transmission: a study of a family cluster. Lancet. 2020;395(10223):514 23.

  83. Duan Y N, Qin J. Pre and posttreatment chest CT findings: 2019 novel coronavirus (2019 nCoV) pneumonia. Radiology. 2020 Feb. 12:200323.

  84. The 2019 nCoV Outbreak Joint Field Epidemiology Investigation Team 1,2,3; Qun L. An outbreak of NCIP (2019 nCoV) infection in China Wuhan, Hubei Province, 2019−2020 ìnternet]. China: CCDC Weekly. 2020 Jan. 24 [citado 6 mayo 2020]. Disponible en: https://afludiary. blogspot. com/2 020/01/ccdc weekly outbreak of ncip 2019 ncov. html

  85. Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle. J Med Virol. 2020;92(4):401 2.

  86. Hung IF, Cheng VC, Wu AK, Tang BS, Chan K, Chu C, et al. Viral loads in clinical specimens and SARS manifestations. Emerg Infect Dis. 2004 Sep. ;10(9):1550 7.

  87. Holshue ML, De Bolt C, Lindquis S, Lofy K, Wiesman J, Bruce H, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020;382:929 36.

  88. Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses drug discovery and therapeutic options. Nat Rev Drug Discov. 2016;15(5):327 47.

  89. Li H, Wang YM, Xu JY, Cao B. Potential antiviral therapeutics for 2019 Novel Coronavirus. Chin J Tuberc Respir Dis. 2020;43(0):E002

  90. Arabi YM, Mandourah Y, Al Hameed F, Annes S. Corticosteroid therapy for critically Ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med. 2018 Mar. 15;197(6):757 67.

  91. World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected [internet]. Geneva: WHO; 2020 [citado 30 ene. 2020]. Disponible en: https://www. who. int/publications/i/item/clinical management of covid 19

  92. Xiao JZ, Ma L, Gao J, Yang ZJ, Xing XY, Zhao HC, et al. Glucocorticoid induced diabetes in severe acute respiratory syndrome: the impact of h igh dosage and duration of methylprednisolone therapy. Zhonghua Nei Ke Za Zhi. 2004;43:179e82.

  93. Zhao JP, Hu Y, Du RH. Expert consensus on the use of corticosteroid in patients with 2019 nCoV pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43:E007.

  94. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019 nCoV lung injury. Lancet. 2020;395:473 5.

  95. Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, et al. Coronavirus infections and immune responses. J Med Virol. 2020;92:424e32.

  96. A gostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, et al. Coronavirus susceptibility to the antiviral remdesivir (gs 5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio. 2018;9(2):e0022 1 18.

  97. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019 nCoV) in vitro. Cell Res. 2020 Feb. 4;30:269 71.

  98. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID 19: a randomised, double blind, placebo controlled, multicentre trial. Lancet. 2020 May;395(10236):1569 78.

  99. Multicenter collaboration group of Department of Scien ce and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia. Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. 2020 Feb. 20;43(0):E019.

  100. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect Dis. 2003;3(11):7227.

  101. Golden EB, Cho HY, Hofman FM, Louie SG, Schonthal AH, Chen TC. Quinoline based antimalarial drugs: a novel class of autophagy inhibitors. Neurosurg Focus. 2015;38(3):E12.

  102. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al. Chloroquine is a potent inhib itor of SARS coronavirus infection and spread. Virol J. 2005;2:69.

  103. Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID 19: a multinational registry analysis. Lancet. 2020 May ;

  104. Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs. 2003;63(8):769 802.

  105. Arabi YM, Asiri AY, Assiri AM, Aziz Jokhdar HA, Alothman A, Balkhy HH, et al. Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon β 1b (MIRACLE trial): statistical analysis plan for a recursive two stage group sequential randomized controlled trial. Trials. 2020;21(1):8.

  106. Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59(3):252 6.

  107. Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ, et al. Case of the index patient who caused tertiary transmission of COVID 19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID 19 infected pneumonia monitored by quantitative RT PCR. J Korean Med Sci. 2020;35(6):e79.

  108. Chen L, Xiong J, Bao L, Shi Y. Convalesce nt plasma as a potential therapy for COVID 19. Lancet Infect Dis. 2020;4:398 400.

  109. Li J, Li J, Xie X. Game consumption and the 2019 novel coronavirus. Lancet Infect Dis. 2020;3:275 6.

  110. Vincent JM, Marion K, Van Doremalen N. A novel coronavirus emer ging in China key questions for impact assessment. N Engl J Med. 2020;382:692 4.

  111. Wenjie T. A novel coronavirus genome identified in a cluster of pneumonia cases wuhan, China 2019−2020, China. CDC Weekly. 2020;2(4):61 2.

  112. National Health Commission of People’s Republic of China. Pneumonia infected with novel coronavirus is included in the management of legal infectious diseases [internet]. China; 2020 [citado 31 ene. 2020]. Disponible en: http://en. nhc. gov. cn/ 2020

  113. Wei Q, Ren Z. Disinfection measures for pneumonia foci infected by novel coronavirus in 2019. Chin J Disinfect. 2020;37:59 62.

  114. Ou F, Wu H, Yang Y, Tan W, Zhang J, Gu J. Counter measures for rapid spread of new coronavirus pneumonia in Wuhan. China Gen Pract Nurs [internet]. 2020 [citado 2 feb. 2020]. Disponible en: http://kns. cnki. net/kcms/detail/14. 1349. R. 20200131. 1319. 002. html

  115. World Health Organization. Coronavirus disease [COVID 19] Technical Guidance: Infection Prevention and Control [internet]. Geneva: WHO; 2020 [citado 20 feb. 2020]. Disponible en: https://www. who. int/publications/i/item/clinical management of covid 19

  116. World Health Organization. Advice on the use of masks in the community, during home care and in health care settings in the context of the novel coronavirus 2019 nCo V outbreak (Interim guidance) [internet]. Geneva: WHO; 2020 [citado 3 feb. 2020]. Disponible en: https://www. who. int/publications/i/item/clinical management of covid 19

  117. Centers for Disease Control and Prevention. Interim infection prevention and control recommendations for patients with known or patients under investigation for 2019 novel coronavirus (2019 nCoV) in a healthcare setting [internet]. United States: CDC ; 2020 [citado 3 feb. 2020]. Disponible https://www. cdc. gov/coronavirus/2019 ncov/hcp/guidance home care. html

  118. Green A. Li Wenliang. Lancet [internet]. 2020 Feb. 29 [citado 4 abr. 2020];395(10225):[aprox. 1 p. ]. Disponible en: https://www. thelancet. com/journals/lancet/article/PIIS0140 6736(20)30382 2/fulltext




2020     |     www.medigraphic.com